Assess whether scientific advice should be sought before the next trial

SITUATION Biosimilar analytical similarity report arrived with a literature paper the 505(b)(2) package leans on getting retracted for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences CMC and Development Pathways decision on scientific advice should be in a mid-size sponsor after a complete response letter.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. Biosimilar analytical similarity report reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population. 2. Biosimilar analytical similarity report is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in biosimilar analytical similarity report for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter. 4. Biosimilar analytical similarity report is missing the fact pharmacovigilance medical reviewer needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether biosimilar analytical similarity report supports the labeled claim pharmacovigilance medical reviewer would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on scientific advice should be, then the evidence in biosimilar analytical similarity report, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in biosimilar analytical similarity report that a second reviewer can re-perform